Peng Chen1, Paolo Piaggi1, Michael Traurig1, Clifton Bogardus1, William C Knowler1, Leslie J Baier1, Robert L Hanson2. 1. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1550 E. Indian School Rd, Phoenix, AZ, 85014, USA. 2. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1550 E. Indian School Rd, Phoenix, AZ, 85014, USA. rhanson@phx.niddk.nih.gov.
Abstract
AIMS/HYPOTHESIS: Individuals exposed to maternal diabetes in utero are more likely to develop metabolic and cardiovascular diseases later in life. This may be partially attributable to epigenetic regulation of gene expression. We performed an epigenome-wide association study to examine whether differential DNA methylation, a major source of epigenetic regulation, can be observed in offspring of mothers with type 2 diabetes during the pregnancy (OMD) compared with offspring of mothers with no diabetes during the pregnancy (OMND). METHODS: DNA methylation was measured in peripheral blood using the Illumina HumanMethylation450K BeadChip. A total of 423,311 CpG sites were analysed in 388 Pima Indian individuals, mean age at examination was 13.0 years, 187 of whom were OMD and 201 were OMND. Differences in methylation between OMD and OMND were assessed. RESULTS: Forty-eight differentially methylated CpG sites (with an empirical false discovery rate ≤0.05), mapping to 29 genes and ten intergenic regions, were identified. The gene with the strongest evidence was LHX3, in which six CpG sites were hypermethylated in OMD compared with OMND (p ≤ 1.1 × 10-5). Similarly, a CpG near PRDM16 was hypermethylated in OMD (1.1% higher, p = 5.6 × 10-7), where hypermethylation also predicted future diabetes risk (HR 2.12 per SD methylation increase, p = 9.7 × 10-5). Hypermethylation near AK3 and hypomethylation at PCDHGA4 and STC1 were associated with exposure to diabetes in utero (AK3: 2.5% higher, p = 7.8 × 10-6; PCDHGA4: 2.8% lower, p = 3.0 × 10-5; STC1: 2.9% lower, p = 1.6 × 10-5) and decreased insulin secretory function among offspring with normal glucose tolerance (AK3: 0.088 SD lower per SD of methylation increase, p = 0.02; PCDHGA4: 0.08 lower SD per SD of methylation decrease, p = 0.03; STC1: 0.072 SD lower per SD of methylation decrease, p = 0.05). Seventeen CpG sites were also associated with BMI (p ≤ 0.05). Pathway analysis of the genes with at least one differentially methylated CpG (p < 0.005) showed enrichment for three relevant biological pathways. CONCLUSIONS/ INTERPRETATION: Intrauterine exposure to diabetes can affect methylation at multiple genomic sites. Methylation status at some of these sites can impair insulin secretion, increase body weight and increase risk of type 2 diabetes.
AIMS/HYPOTHESIS: Individuals exposed to maternal diabetes in utero are more likely to develop metabolic and cardiovascular diseases later in life. This may be partially attributable to epigenetic regulation of gene expression. We performed an epigenome-wide association study to examine whether differential DNA methylation, a major source of epigenetic regulation, can be observed in offspring of mothers with type 2 diabetes during the pregnancy (OMD) compared with offspring of mothers with no diabetes during the pregnancy (OMND). METHODS: DNA methylation was measured in peripheral blood using the Illumina HumanMethylation450K BeadChip. A total of 423,311 CpG sites were analysed in 388 Pima Indian individuals, mean age at examination was 13.0 years, 187 of whom were OMD and 201 were OMND. Differences in methylation between OMD and OMND were assessed. RESULTS: Forty-eight differentially methylated CpG sites (with an empirical false discovery rate ≤0.05), mapping to 29 genes and ten intergenic regions, were identified. The gene with the strongest evidence was LHX3, in which six CpG sites were hypermethylated in OMD compared with OMND (p ≤ 1.1 × 10-5). Similarly, a CpG near PRDM16 was hypermethylated in OMD (1.1% higher, p = 5.6 × 10-7), where hypermethylation also predicted future diabetes risk (HR 2.12 per SD methylation increase, p = 9.7 × 10-5). Hypermethylation near AK3 and hypomethylation at PCDHGA4 and STC1 were associated with exposure to diabetes in utero (AK3: 2.5% higher, p = 7.8 × 10-6; PCDHGA4: 2.8% lower, p = 3.0 × 10-5; STC1: 2.9% lower, p = 1.6 × 10-5) and decreased insulin secretory function among offspring with normal glucose tolerance (AK3: 0.088 SD lower per SD of methylation increase, p = 0.02; PCDHGA4: 0.08 lower SD per SD of methylation decrease, p = 0.03; STC1: 0.072 SD lower per SD of methylation decrease, p = 0.05). Seventeen CpG sites were also associated with BMI (p ≤ 0.05). Pathway analysis of the genes with at least one differentially methylated CpG (p < 0.005) showed enrichment for three relevant biological pathways. CONCLUSIONS/ INTERPRETATION: Intrauterine exposure to diabetes can affect methylation at multiple genomic sites. Methylation status at some of these sites can impair insulin secretion, increase body weight and increase risk of type 2 diabetes.
Entities:
Keywords:
DNA methylation; Diabetes in pregnancy; Differentially methylated region; Maternal diabetes exposure in utero
Authors: R L Hanson; R E Pratley; C Bogardus; K M Narayan; J M Roumain; G Imperatore; A Fagot-Campagna; D J Pettitt; P H Bennett; W C Knowler Journal: Am J Epidemiol Date: 2000-01-15 Impact factor: 4.897
Authors: H Maegawa; K Shi; H Hidaka; N Iwai; Y Nishio; K Egawa; H Kojima; M Haneda; H Yasuda; Y Nakamura; M Kinoshita; R Kikkawa; A Kashiwagi Journal: Diabetes Date: 1999-07 Impact factor: 9.461
Authors: Morgan S Gadd; David A Jacques; Ivan Nisevic; Vanessa J Craig; Ann H Kwan; J Mitchell Guss; Jacqueline M Matthews Journal: J Biol Chem Date: 2013-06-09 Impact factor: 5.157
Authors: Mary Beth Terry; Jennifer S Ferris; Richard Pilsner; Julie D Flom; Parisa Tehranifar; Regina M Santella; Mary V Gamble; Ezra Susser Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: Muideen T Olaiya; Lauren E Wedekind; Robert L Hanson; Madhumita Sinha; Sayuko Kobes; Robert G Nelson; Leslie J Baier; William C Knowler Journal: Diabetologia Date: 2019-05-20 Impact factor: 10.122
Authors: Line Hjort; David Martino; Louise Groth Grunnet; Haroon Naeem; Jovana Maksimovic; Anders Henrik Olsson; Cuilin Zhang; Charlotte Ling; Sjurdur Frodi Olsen; Richard Saffery; Allan Arthur Vaag Journal: JCI Insight Date: 2018-09-06
Authors: Sara E Pinney; Apoorva Joshi; Victoria Yin; So Won Min; Cetewayo Rashid; David E Condon; Paul Zhipang Wang Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958
Authors: Dianna J Magliano; Julian W Sacre; Jessica L Harding; Edward W Gregg; Paul Z Zimmet; Jonathan E Shaw Journal: Nat Rev Endocrinol Date: 2020-03-20 Impact factor: 43.330